After careful evaluation of both arguments, the bear case carries the heavier weight in the near term, though this is not a structural short. The bull makes a compelling fundamental case — 47% Q2 revenue growth, 54% operating margins, 102% ROE, Mounjaro CV approval, China first-mover lead. But the bear scored three points the bull never adequately answered: (1) sequential EPS declined from $8.26 in Q1 2026 to $7.94 in Q2 — that's a real deceleration flag that undermines the "59% forward growth" narrative; (2) the Mounjaro CV approval stock peaked Aug 19 at $1,292 — likely a sell-the-news event given the 9% subsequent drawdown; and (3) the technical setup is broken on three confirming signals (price below 10 EMA, below 50 SMA, MACD histogram expanding to -6.46), not just one. Combined with intangibles up 131% from M&A binge, 19% premium to S&P 500 forward earnings, uniform bullish consensus (classic contrarian warning), and a macro duration-compression backdrop (89% probability of no Fed cuts in 2026), the risk/reward asymmetry favors trimming. The underlying franchise remains world-class — this is a timing and positioning call, not a thesis rejection. Hold a smaller position sized for the volatility, avoid adding into broken technicals, and wait for either a 200 SMA retest (~$1,056) or a confirmed reclaim of the 10 EMA with bullish MACD cross before re-engaging.

POSITION REDUCTION: Reduce existing LLY exposure by approximately 25-40% of overweight position to bring weight to slightly below benchmark.

HEDGING: For remaining core holding, layer in 3-month protective puts roughly 5-8% out-of-the-money to hedge against a 200 SMA retest scenario ($1,056) — implied vol is currently elevated enough to make this manageable.

STOP-LOSS DISCIPLINE: Set hard stop-loss discipline at $1,155 (just below current price); a sustained break below $1,117 lower Bollinger Band should trigger further trimming toward underweight 2.0.

ENTRY CONDITIONS: Do NOT initiate new buying until either: (a) a flush to the 200 SMA at ~$1,056 with capitulation volume, OR (b) a confirmed reclaim of the 10 EMA at $1,206 with MACD histogram crossing back positive and volume expansion.

CATALYST MONITORING: Q3 2026 earnings (expected late October/early November) is the next major catalyst — wait for print and updated guidance before re-evaluating sizing. Watch for: any sequential EPS improvement, gross-to-net stabilization commentary, and obesity cash-pay reimbursement trends.

SENTIMENT TRACKING: Monitor insider transactions and 13F filings for institutional rotation signals; if major holders begin trimming, accelerate the underweight.

RE-ENGAGE TARGET: Re-assess at $1,250+ reclaim with conviction; a move back above $1,292 ATH on CV-label prescription data would be the signal to revisit.

The Underweight recommendation is well-supported by three confirming technical breakdowns (price below 10 EMA, below 50 SMA, expanding negative MACD histogram at -6.46), a sequential EPS deceleration from $8.26 to $7.94 that undercuts the "59% forward growth" narrative, and a likely sell-the-news reaction to the Mounjaro CV approval (stock peaked Aug 19 at $1,292 and has since drawn down ~9%). Macro headwinds — 89% probability of no 2026 Fed cuts and duration compression — disproportionately impact LLY's 19% premium multiple to S&P 500 forward earnings, while uniform bullish consensus is a classic contrarian warning. Trimming 25-40% of the overweight position into this broken technical setup is the right tactical move; the world-class GLP-1 franchise remains intact, so this is a sizing/timing call, not a thesis rejection.

Stop loss: $1155.00

Sizing: Trim 25-40% of existing LLY position; reduce portfolio weight to slightly below benchmark; layer 3-month protective puts 5-8% OTM on remaining core holding